通过 T 细胞受体基因转移进行免疫疗法会引发严重的移植物抗宿主病。
Immunotherapy through T-cell receptor gene transfer induces severe graft-versus-host disease.
机构信息
Department of Pediatrics, University of Michigan, Ann Arbor, MI 48109, USA.
出版信息
Immunotherapy. 2010 Nov;2(6):791-4. doi: 10.2217/imt.10.73.
Abstract
Evaluation of: Bendle GM, Linnemann C, Hooijkaas AI et al.: Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med. 16(5), 565-570 (2010). Graft-versus-host disease is commonly associated with allogeneic hematopoietic cell transplantation, as it is the major complication. This article reports that, after immunotherapy with lymphocytes that have been transduced with T-cell receptor (TCR) genes of known specificity, graft-versus-host disease can occur through TCR gene transfer. This autoimmune pathology occurs through the formation of self-reactive TCRs as a result of one chain of the transduced TCR cross-pairing with an endogenous TCR. Certain adjustments in the design of gene therapy vectors may help reduce the risk of such autoimmune phenomena.
摘要
评价
Bendle GM、Linnemann C、Hooijkaas AI 等人：T 细胞受体基因治疗小鼠模型中的致命移植物抗宿主病。自然医学 16(5), 565-570 (2010)。移植物抗宿主病通常与同种异体造血细胞移植相关，因为它是主要并发症。本文报道，在用已知特异性 T 细胞受体 (TCR) 基因转导的淋巴细胞进行免疫治疗后，移植物抗宿主病可能通过 TCR 基因转移发生。这种自身免疫病理学是由于转导的 TCR 的一条链与内源性 TCR 交叉配对而形成自身反应性 TCR 所致。基因治疗载体设计的某些调整可能有助于降低此类自身免疫现象的风险。
相似文献
1
Immunotherapy through T-cell receptor gene transfer induces severe graft-versus-host disease.通过 T 细胞受体基因转移进行免疫疗法会引发严重的移植物抗宿主病。
Immunotherapy. 2010 Nov;2(6):791-4. doi: 10.2217/imt.10.73.
2
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy.T 细胞受体基因治疗的小鼠模型中的致命移植物抗宿主病。
Nat Med. 2010 May;16(5):565-70, 1p following 570. doi: 10.1038/nm.2128. Epub 2010 Apr 18.
3
HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.HA-1H T 细胞受体基因转导重定向病毒特异性 T 细胞用于异基因干细胞移植后血液系统恶性肿瘤的治疗：一项 1 期临床研究。
Front Immunol. 2020 Aug 20;11:1804. doi: 10.3389/fimmu.2020.01804. eCollection 2020.
4
An Ig Transmembrane Domain Motif Improves the Function of TCRs Transduced in Human T Cells: Implications for Immunotherapy.Ig 跨膜结构域基序可改善人 T 细胞中转导的 TCR 功能：对免疫疗法的影响。
J Immunother. 2019 May;42(4):97-109. doi: 10.1097/CJI.0000000000000259.
5
PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.PD-L1 阻断有效地恢复了强烈的移植物抗白血病效应，而在延迟过继转移 T 细胞受体基因工程同种异体 CD8+ T 细胞后没有移植物抗宿主病。
Blood. 2011 Jan 20;117(3):1030-41. doi: 10.1182/blood-2010-04-283119. Epub 2010 Nov 9.
6
Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.新型 WT1 特异性 TCR 载体的过继性 T 细胞免疫疗法，该载体编码内源性 TCR 沉默子，表现出显著的抗白血病反应性和安全性。
Blood. 2011 Aug 11;118(6):1495-503. doi: 10.1182/blood-2011-02-337089. Epub 2011 Jun 14.
7
Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.造血干细胞移植操作作为一种免疫治疗机制。
Int Immunopharmacol. 2003 Aug;3(8):1121-43. doi: 10.1016/S1567-5769(03)00014-6.
8
Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.供体淋巴细胞输注：将同种异体反应性和肿瘤反应性淋巴细胞用于恶性和非恶性疾病的免疫治疗，并与异基因干细胞移植联合使用。
J Hematother Stem Cell Res. 2002 Apr;11(2):265-76. doi: 10.1089/152581602753658457.
9
Adoptive immunotherapy of disseminated leukemia with TCR-transduced, CD8+ T cells expressing a known endogenous TCR.采用表达已知内源性TCR的经TCR转导的CD8+T细胞对播散性白血病进行过继性免疫治疗。
Mol Ther. 2009 Apr;17(4):742-9. doi: 10.1038/mt.2008.300. Epub 2009 Feb 10.
10
HLA-DPB1 Reactive T Cell Receptors for Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation.HLA-DPB1 反应性 T 细胞受体用于异基因造血干细胞移植中的过继免疫治疗。
Cells. 2020 May 20;9(5):1264. doi: 10.3390/cells9051264.
引用本文的文献
1
Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy.实体瘤中TCR-T细胞疗法的新见解：优化过继性免疫疗法。
Exp Hematol Oncol. 2024 Apr 3;13(1):37. doi: 10.1186/s40164-024-00504-8.
2
CAR NK Cell Therapy for the Treatment of Metastatic Melanoma: Potential & Prospects.嵌合抗原受体自然杀伤（CAR-NK）细胞疗法治疗转移性黑色素瘤：潜力与展望。
Cells. 2023 Nov 30;12(23):2750. doi: 10.3390/cells12232750.
3
TCR-T Immunotherapy: The Challenges and Solutions.TCR-T免疫疗法：挑战与解决方案
Front Oncol. 2022 Jan 25;11:794183. doi: 10.3389/fonc.2021.794183. eCollection 2021.
4
Sarcoma Tumor Microenvironment.肉瘤肿瘤微环境。
Adv Exp Med Biol. 2020;1296:319-348. doi: 10.1007/978-3-030-59038-3_20.
5
CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy.CRISPR-Cas，现代癌症免疫治疗时代一项强大的基因编辑技术。
Cancer Cell Int. 2020 Sep 15;20:456. doi: 10.1186/s12935-020-01546-8. eCollection 2020.
本文引用的文献
1
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.用白细胞介素 15 和自杀基因工程改造 CD19 特异性 T 淋巴细胞，以增强其抗淋巴瘤/白血病效应和安全性。
Leukemia. 2010 Jun;24(6):1160-70. doi: 10.1038/leu.2010.75. Epub 2010 Apr 29.
2
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy.T 细胞受体基因治疗的小鼠模型中的致命移植物抗宿主病。
Nat Med. 2010 May;16(5):565-70, 1p following 570. doi: 10.1038/nm.2128. Epub 2010 Apr 18.
3
Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?".基于嵌合抗原受体的基因治疗 15 年：“我们快成功了吗？”。
Hum Gene Ther. 2009 Nov;20(11):1229-39. doi: 10.1089/hum.2009.142.
4
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.使用人类和小鼠T细胞受体的基因疗法介导癌症消退，并靶向表达同源抗原的正常组织。
Blood. 2009 Jul 16;114(3):535-46. doi: 10.1182/blood-2009-03-211714. Epub 2009 May 18.
5
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.白血病患者接受单倍体相合造血干细胞移植后输注自杀基因工程供体淋巴细胞（TK007试验）：一项非随机的I-II期研究
Lancet Oncol. 2009 May;10(5):489-500. doi: 10.1016/S1470-2045(09)70074-9. Epub 2009 Apr 1.
6
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.经过基因工程改造以共表达肿瘤特异性受体的病毒特异性T细胞：在神经母细胞瘤患者中的持久性和抗肿瘤活性
Nat Med. 2008 Nov;14(11):1264-70. doi: 10.1038/nm.1882. Epub 2008 Nov 2.
7
Adoptive cell transfer: a clinical path to effective cancer immunotherapy.过继性细胞转移：有效癌症免疫疗法的临床途径。
Nat Rev Cancer. 2008 Apr;8(4):299-308. doi: 10.1038/nrc2355.
8
Dual T cell receptor expressing CD8+ T cells with tumor- and self-specificity can inhibit tumor growth without causing severe autoimmunity.表达具有肿瘤特异性和自身特异性的双T细胞受体的CD8 + T细胞可抑制肿瘤生长而不引起严重自身免疫。
J Immunol. 2007 Oct 15;179(8):5534-42. doi: 10.4049/jimmunol.179.8.5534.
9
Transfusion-associated graft-versus-host disease in immunocompetent patients: case series and review of the literature.免疫功能正常患者的输血相关移植物抗宿主病：病例系列及文献综述
Transfusion. 2007 Aug;47(8):1405-11. doi: 10.1111/j.1537-2995.2007.01282.x.
10
Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.经工程改造以表达带有第二个二硫键的T细胞受体的T细胞，其抗肿瘤活性增强。
Cancer Res. 2007 Apr 15;67(8):3898-903. doi: 10.1158/0008-5472.CAN-06-3986.
Zotero 插件